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Abstract
Genome-wide association studies (GWAS) examine a large number of markers across the genome to identify associations
between genetic variants and disease. Most published studies examine only single markers, which may be less informative
than considering multiple markers and multiple genes jointly because genes may interact with each other to affect disease
risk. Much knowledge has been accumulated in the literature on biological pathways and interactions. It is conceivable that
appropriate incorporation of such prior knowledge may improve the likelihood of making genuine discoveries. Although a
number of methods have been developed recently to prioritize genes using prior biological knowledge, such as pathways,
most methods treat genes in a specific pathway as an exchangeable set without considering the topological structure of a
pathway. However, how genes are related with each other in a pathway may be very informative to identify association
signals. To make use of the connectivity information among genes in a pathway in GWAS analysis, we propose a Markov
Random Field (MRF) model to incorporate pathway topology for association analysis. We show that the conditional
distribution of our MRF model takes on a simple logistic regression form, and we propose an iterated conditional modes
algorithm as well as a decision theoretic approach for statistical inference of each gene’s association with disease.
Simulation studies show that our proposed framework is more effective to identify genes associated with disease than a
single gene–based method. We also illustrate the usefulness of our approach through its applications to a real data
example.
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Introduction
In genome-wide association studies (GWAS) researchers
examine a large number of markers across the genome in many
individuals to identify associations between genetic variants and
disease, or to prioritize markers for follow up studies. However,
most of the times the signals from individual markers are weak and
the sample size is not large enough to have adequate power for
true discoveries, especially when the minor allele frequency is low.
Various approaches have been developed to increase statistical
power, including aggregating multiple markers from the same
gene or in the same haplotype block region and incorporating
information from other sources into the GWAS analysis. It has
been found that the gene level analysis has the ability to identify
new associations in addition to those identified using individual
Single Nucleotide Polymorphisms (SNPs) [1,2]. Gene-based
analyses include those using the most significant SNP within and
near a gene [1]; combination statistics (Fisher, Sidat, and Simes)
from all individual markers [2]; Principal Component Analysis
(PCA) regressions [3] and the sparse partial least squares
regressions [4]. To incorporate prior biological knowledge, one
information rich resource is biological pathways. It is believed that
genes interact with each other in biological processes, and it is
conceivable that they may jointly affect the risk of a complex
disease. There exist an abundance of databases containing known
gene pathways and protein-protein interactions, such as KEGG,
BioCarta, GenMAPP, and HPRD. A number of gene prioritiza-
tion methods incorporating prior biological knowledge have been
developed for GWAS. Some examples include Prioritizer [5],
Endeavour [6], CGI [7], CANDID [8], GeneWanderer [9],
CIPHER [10], GIN [11], and the pathway based gene set
enrichment approach [1]. These methods have shown that
incorporating prior biological information in GWAS is useful.
However, they do not consider functional relationships among
genes. The general input of these approaches is a list of genes as a
set, in which genes are treated as exchangeable without taking into
account the regulatory relationships among them. As a result,
information from the pathway topology and interactions among
genes is usually ignored. However, how genes are functionally
related to each other in a pathway may be very informative for
GWAS analysis and such information can be utilized to increase
the power of detecting real associations. When associations have
been firmly established for some genes either through GWAS or
prior candidate gene-based studies, we can take advantage of this
knowledge to examine other genes related to these known genes
through the same pathways they all participate in.
In this paper we propose a Markov Random Field (MRF) model
to incorporate biological pathway information in GWAS. MRF
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different sources in genomics studies, e.g., a spatial normal mixture
model [12] for gene expression and CHIP-chip data, a Gamma-
Gamma model and MRF for mRNA microarray data [13], and
prioritizing genes by combining gene expression and protein
interaction data [7]. However, little has been done in the context
for GWAS, with the exception of Li et al. [14] who proposed a
hidden MRF for GWAS. But their method is developed in the
context of jointly analyzing markers in linkage disequilibrium.
We first present a motivating example from a GWAS of Crohn’s
disease [15] for the proposed method. As will be shown next, the
result clearly suggests that genes in the same neighborhood within
a pathway tend to show similar association status. This Crohn’s
disease cohort includes 401 cases and 433 controls, and the
Illumina HumanHap300 BeadChip (Illumina, San Diego) were
used for genotyping. We first mapped SNPs to genes and then
applied PCA regressions to obtain gene-level p values of the
association tests with Crohn’s disease status [3]. More details about
this data set are given in the Materials and Methods section. We
then obtained pathway and interaction from BioCarta (http://
www.biocarta.com/), GeneMAPP [16] and KEGG [17]. We
consider a total of 3,735 genes in over 350 pathways. Genes on the
same chromosome that are within 1 million base pairs are
excluded to avoid effects caused by possible linkage disequilibrium.
To see whether genes connected with each other in the same
pathway tend to show similar evidence for association, we use a
cut-off value 0.15 where genes whose p values are below this cut-
off are considered interesting and labeled with 1. Note that we use
a relatively loose threshold so that a sufficiently large number of
genes are called ‘‘interesting’’ and this loose cut-off also reflects our
belief that many genes have weak effects and only show moderate
evidence of association. In a pathway k, we consider the number
of edges connecting a pair of ‘‘interesting’’ genes, which depends
on the labels of all genes. We denote this number by Dk. A large
value of Dk would suggest that ‘‘interesting’’ genes are more likely
to be neighboring genes. To assess the statistical evidence for the
tendency to observe large Dk values, we employ a permutation
procedure as follows. In each permutation, we randomly permute
the ‘‘interesting’’ labels of all genes and derive a permuted statistic
and these permuted statistics are used to arrive at an empirical
distribution of Dk under the null hypothesis that there is no
tendency for neighboring genes to have similar disease association
status, i.e. ‘‘interesting’’ or not. We then compare the observed Dk
statistic with the empirical distribution. Finally the p value of the
observed Dk in this empirical distribution is calculated. A p value
close to 0 indicates that ‘‘interesting’’ genes tend to be neighbors.
This procedure is repeated for all pathways, and the histogram of p
values of Dk for all pathways is plotted in Figure 1. It is evident
that this distribution is highly skewed to the left, which suggests
associated genes tend to be neighbors in a given pathway.
In the rest of this article, we first introduce our model and statistical
inferential procedures. The performance of our methods is then
assessed through both simulation studies and real data applications.
Author Summary
Statistical methods used in most GWAS are based on the
analysis of single markers. Prior biological information about
markers, genes, and pathways is not commonly incorporated
in the detection of associated disease loci. Recently a number
of methods have been developed to incorporate such
information, and it has been shown that they may make
use of prior biological knowledge in association analysis.
However, most of these methods ignore the regulatory
relationships and functional interactions among genes. In
thisarticle, wepropose a statistical method that can explicitly
model the interactions of genes in a neighborhood defined
by the topology of a pathway. Simulation studies and a real
data example show that the proposed method can improve
the power of identifying associated genes when they are in
the neighborhood of other genes whose association has
been firmly established in previous studies.
Figure 1. Histogram of p values of Dk, the number of edges connecting a pair of ‘‘interesting’’ genes in a pathway k, which depends
on the labels of all genes. A large value of Dk would suggest that ‘‘interesting’’ genes are more likely to be neighbors. A permutation procedure is
used to derive an empirical distribution of Dk under the null hypothesis. The p value of an observed Dk is calculated with respect to this empirical
distribution. See the Introduction section for more details.
doi:10.1371/journal.pgen.1001353.g001
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A MRF model of gene pathways
We start by considering a simple model in which a pathway is
represented by an undirected graph G~(V,E) where V~
f1,   ,ng is a set of n genes (nodes) and E~fvi,jw : i and j
are directly connected} denotes the set of all edges. For the ith
gene in V, let Ni~fj : vi,jw[ Eg denote the set of its neighbors,
and di~DNiD denote the number of its neighbors. Let Si denote the
true association status where
Si~z1 if gene i is associated with the disease,
Si~{1 if gene i is NOT associated with the disease:
The values +1 are referred to as labels of a node hereafter. Let
S~(S1,   ,Sn) denote the labeling of V. Thus S is a spatial
random vector whose elements may be correlated with each other.
Note that each node can be labeled either {1 or z1, and so there
are a total of 2n unique configurations of the pathway. The
ultimate goal is to infer the value of Si based on the pathway
topology and the observed association data.
To formalize the idea that neighboring genes tend to have
similar association status, we need a probability measure so that
nodes connected with each other tend to have the same labels.
Here we consider a nearest neighbor Gibbs measure [18] that has
the following form:
Pr(Sjh0)~
1
z(h0)
exp
h
X
i [ V
I1(Si)zt0
X
vi,jw[ E
(wizwj)I{1(Si)I{1(Sj)
(
z
t1
X
vi,jw[ E
(wizwj)I1(Si)I1(Sj)
)
,
ð1Þ
where h0~(h,t1,t0) are the prior parameters or hyperparameters,
I1(:) and I{1(:) are the indicator functions, wi~d
1=2
i , and z(h0) is
a normalizing function that is the sum over all 2n possible
configurations:
z(h0)~
X
S
exp h
X
i [ V
I1(Si)zt0
X
vi,jw[ E
(wizwj)I{1(Si)I{1(Sj)z
(
t1
X
vi,jw[ E
(wizwj)I1(Si)I1(Sj)
)
:
ð2Þ
Note that it is prohibitive to evaluate z(h0) when n is large. Here
t0 and t1 assign prior weights to edges connecting two non-
associated nodes and two associated nodes, respectively. The
function wi will be elaborated in more details in the context of the
conditional probability later.
In (1), the second sum is taken over all edges connecting direct
neighbors in which both end nodes are labeled 21, and the third
sum is taken over all edges in which both end nodes are labeled 1.
Positive t0 and t1 will put more weights on configurations in which
directly linked nodes have the same labels, which is desirable in
our context. The hyperparameter h determines the marginal
probability of Si when t0~t1~0, i.e., all nodes are treated as
singletons that are independent:
Pr(Si~1Dh,t0~t1~0)~
exp(h)
exp(h)z1
:
The simple form Gibbs measure in (1) has the Markov property
that makes it attractive to model a biological pathway, in which
directly linked genes interact with each other. It defines a MRF,
which by definition is a probability measure that satisfies
Pr(SiDSV{i)~Pr(SiDSNi), where V{i denote all nodes but i,
and Ni is the set of all direct neighbors of node i. Please see
Materials and Methods for details.
Posterior distribution
Now we discuss the posterior distribution of association status
after combining the evidence from the observed association
statistics at the gene level and the structure of the gene
pathway. Before we proceed, it is necessary to present the
likelihood function of the observed data. We consider the
situation where the observed evidence of association is
summarized by p values, which are assumed to be conditionally
independent given the true association status S.U n d e rt h en u l l
hypothesis of no association, each p-value has a uniform (0,1)
distribution. In this article, we consider y~(y1,   ,yn),w h e r e
yi~W{1(1{pi=2) and W(:) is the CDF (Cumulative Distribu-
tion Function) of N(0,1). Therefore, under the null hypothesis
of no association, i.e., Si~{1, the density of yi is
f0(yi)*N(0,1). However, if there is association between the
gene and disease, i.e., Si~z1, the distribution of yi is usually
unknown. For simplicity, we assume that it is from N(mi,s2
i ),
where mi is the location parameter and si is the scale parameter
that usually depends on the true effect size, allele frequencies,
and the sample size. To account for the uncertainty about the
parameters, we can put prior distributions on mi and s2
i ,a n d
marginalize over them to obtain the predictive density of yi.
Here we consider conjugate priors miDs2
i *N(  m m,s2
i =a) and
s2
i *Inverse Gamma(n=2,nd=2),o rnd=s2
i *x2
n: We denote
h1~(  m m,a,n,d) that are hyperparameters. The prior mean of mi
is   m m and its variance is s2
i =a.T h ep r i o rm e a no fs{2
i is d{1 and
the prior variance is Var½s{2
i  ~2=(nd2). This prior is of
conjugate form so that the integration over mi and s2
i is
analytically tractable. We note that the hyperparameters can be
estimated from the observed data via an empirical Bayes
method (see Text S2, Figures S1 and S2). Under this prior
setting, the marginal density of yi is
f1(yijSi~1,h1)~p{1=2(nd)
n=2
ﬃﬃﬃ
a
p
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
az1
p
C((nz1)=2)
C(n=2)
a
az1
(yi{  m m)
2znd
   {(1zn)=2
:
This is equivalent to (yi{  m m)=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
(az1)d=a
p
*t(n) when n~1, 2,
and others.
The joint marginal density of y is
f(yDS,h1)~ P
fj:Sj~{1g
f0(yj)| P
fj:Sj~z1g
f1(yiDh1):
Thus, the posterior distribution of S given the observed data y is
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Similar to the MRF interpretation of the prior distribution (1), the
posterior also has a nice conditional distribution and is actually a
MRF, as will be shown in the Materials and Methods section.
When n is large, since it is prohibitive to evaluate posterior
probabilities on the entire space of configurations, we implement a
Markov chain Monte Carlo (MCMC) method to sample from the
posterior distribution. Naturally a Gibbs sampler is well suited for
a MRF. As will be shown later, due to the MRF property, the
posterior has a nice closed-form conditional distribution that can
greatly facilitate the MCMC.
Making inference based on the posterior distribution
Most GWAS lead to a set of candidate genes/SNPs that will
need to be validated in follow-up studies. Therefore, it is important
to include as many truly associated genes as possible among the
top ranked genes. Our proposed method allows us to rank order
genes as detailed below.
There are several ways of inferring the labels according to the
posterior distribution of S. The first one is to use maximum a
posteriori (MAP) estimate, which is the configuration with the largest
posterior probability, a reasonable point estimate for S. Let us
denote it by ^ s sA~(^ s sA
1 ,   ,^ s sA
n ). The MAP is the maximizer of the
joint posterior distribution:
^ s sA~argmax
s
f(yDs,h1)Pr(sDh0):
A Gibbs sampler outlined above can be applied to stochastically
search for the solution to the above optimization problem.
Multiple restarts with different initial configurations are recom-
mended. An alternative approach is to base the estimate on the
posterior conditional probability of Si given the observed data and
all the other nodes sV{i. We can estimate si by maximizing this
conditional probability (MCP):
^ s sC
i ~argmax
si
f(yiDsi,h1)Pr(siDsNi,h0): ð4Þ
The advantage of this approach is that the above problem is trivial
to solve. As will be explained in equation (8) of the Materials and
Methods section, the second term in formula (4) can be evaluated
in closed form. Besag [19] proposed an algorithm known as
iterated conditional modes (ICM) that iteratively updates si. Note
that the convergence of ICM is assured because the posterior is
proportional to
Pr(yDs,h0,h1)~Pr(siDy,sV{i,h0,h1)Pr(sV{iDy,h0,h1),
which never decreases at any iteration because the first term is
non-decreasing and the second one is a constant. So it is easy to
see the ICM will converge to a local maximum in the posterior
distribution. Since the ICM runs fast and usually converges in
several iterations, multiple restarts with different initial configura-
tions are recommended. Finally the resulting configurations can be
compared by evaluating f(yD^ s sC,h1)Pr(^ s sCDh0) up to a normalizing
constant to pick the largest one.
The inference can also be based on the marginal posterior
probability. Let mi~Pr(S1~1Dy). We consider a decision rule in
the form d(mi)~I(mi§m ), where I(:) is an indicator function and
m  is the sought decision threshold. If d(mi)~1, the decision is
positive (also referred to as discovery) and gene i is called to be
associated with the disease. Likewise if d(mi)~0 the decision is
negative. To address the problem of multiple comparisons, we
consider loss functions associated with makingwrong decisions (false
discoveries and false negatives), and solve the decision problem by
minimizing the expectation of the loss functions under the posterior
distribution. Here we consider two loss functions. First, if we are
interested in the 0-1 loss function L1(S,d)~
Xn
i~1 DI1(Si){d(mi)D,
we may want to minimize the expected loss
m 
1~argmin
m  EfL1(S,d)jy,h0,h1g
~argmin
m 
X
S
X n
i~1
jI1(Si){d(mi)j
()
:Pr(Sjy,h0,h1),
ð5Þ
under the posterior distribution of S.T h es o l u t i o ni sm 
1~0:5.N o t e
that L1 assigns equal loss to the false positive and false negative errors.
This is to minimize the expected frequency of making wrong calls for
the association status. Note that the performance of the decision rule d
is based on the frequentist operating characteristic in the Bayesian
framework, which is common in medical decision makings [20]. The
second loss function we consider is the false discovery rate (FDR):
FDR~L2(S,d)~
P
i d(mi)I{1(Si)
P
i d(mi)
: ð6Þ
Suppose the goal is to control the expected FDR, under the
posterior distribution, such that it is no more than a, i.e.,
EfL2(S,d)Dy,h0,h1gƒa. If we rank order all genes by their
posterior probabilities from the largest to the smallest, and let m(i)
denote the ith order statistics, then the solution is to choose a cut
off value m 
2~m(j) where j is the largest integer that makes
j{1 Xj
i~1 m(i)§(1{a). We should mention that more compli-
cated loss functions can be considered under the framework of our
model. See Mu ¨ller et al. [20] for other examples.
Simulation studies
First we use simulated data to study the performance of the
proposed method. The simulation is based on a simple 6-node
network shown in Figure 2. Genes G1 through G3 are assumed to
be associated with the disease (labeled +1) while G4 through G6
are not associated with the disease (labeled 21). Data are
simulated from a disease model as follows. We assume G1, G2
and G3 have independent effects on disease risk and each has a
disease related SNP. The genotypes and minor allele frequencies
of these three SNPs are denoted by (g1,g2,g3) and (p1,p2,p3),
respectively, where gi [ f0,1,2g for i~1,2,3: A multiplicative
genetic model is assumed for the risk of having the disease. More
specifically, for an individual with genotype (g1,g2,g3), the risk is
r0r
g1
1 r
g2
2 r
g3
3 , where r0 is the baseline risk of those carrying two
normal alleles in all three genes, and ri is the relative risk, or effect
size, of gene i, i [ f1,2,3g. For each SNP the Hardy-Weinberg
equilibrium (HWE) is assumed to hold in the general population so
that the genotype probabilities are (1{pi)
2, 2pi(1{pi), and p2
i for
gi~0, 1, and 2, respectively. In the simulation we use three minor
allele frequencies p=(0.05, 0.10, 0.15), three disease prevalence
values k=(0.05, 0.10, 0.15), and six effect sizes r=(1.05, 1.10,
1.15, 1.20, 1.25, 1.30). As a result, there are a total of 54 settings of
(p,k,r), for each of which we first let p1~p2~p3~p and
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obtain the conditional distribution of the genotypes (g1,g2,g3)
given the disease status. Then genotypes of G1, G2 and G3 of 600
cases and 600 controls are simulated according to the conditional
genotype distribution. The p values of the three causal genes are
calculated from a logistic regression of the data. For G4 through
G6, the p values are simulated from Uniform(0,1). The power of
detecting the true association depends on the disease model. In this
case, larger values of relative risk, MAF and prevalence
corresponds to association tests with higher power.
In the simulation we set the hyperparameters (h,t1,t0)=(21,
0.25, 0.01) where more weights are assigned to edges connecting
two associated genes. This corresponds to a prior belief that the
probability of association is roughly between 0.35 and 0.50. The
hyperparameters (  m m,a,n,d) are set to (3, 1, 10, 1) where a large value
of n puts a large prior variance on s2
i , which allows a wide range of
values for both mi and s2
i . For each simulated data set, the posterior
probabilities are enumerated since there are only 64 possible
configurations in this simple example. The simulation is repeated
500 times. We compare the proposed method using the posterior
mean with the one using the p value, and apply cut-off values of 0.7
and 0.05 for posterior probabilities and p values, respectively. For
each simulated data set, we calculate the false positive rate (FPR),
sensitivity (Sens.), and false discovery rate (FDR) by thresholding on
p values and posterior probabilities. In addition, genes can be rank
ordered by the two methods and the area under the Receiver
Operating Characteristic curve (AUC) can be calculated. The
average values of the three rates plus the AUC over the 500
simulated data sets are shown in Table 1. As can be seen, the
proposed method of the posterior probability has higher sensitivity,
smaller false discovery rate, and higher AUC than the p value
thresholding in every setting of the prevalence, MAF and effect size,
while the FPR of both methods are controlled at 0.05.
The second simulation study is based on the network shown in
Figure 3. This network was adapted from BioCarta ‘‘Human Rho
cell motility signaling pathway’’ and we deleted a few genes that
are either absent from our Crohn’s disease data or not connected
to others. We assume three different sets of truly associated genes,
plotted in triangles, rectangles and pentagons, each of which
contains three, five, and seven nodes, respectively. To simulate
different levels in the power of the association tests, for each gene
with Si~z1, the p value is computed from a two-sided z test
where z scores are randomly drawn from N(1,1), N(1:5,1) and
N(2,1), respectively, corresponding to the power 0.16 (low), 0.32
(median) and 0.51 (high) in the association tests. The p values for
Si~{1 are generated randomly from Uniform(0, 1) as before.
To examine the effects of hyperparameters of the network, we
consider eight priors, listed in Table 2, that roughly form four main
groups indexed by numbers 1 through 4, and two subgroups
indexed by letters a and b. For each set of hyperparameters a Gibbs
sampler is run to draw samples from the corresponding prior
distribution, and we can estimate Pr(Si~1), the prior mean, and
Pr(Si~Sj~1) and Pr(Si~Sj~{1) where vi,jw[ E,t h e
probabilities of edge vi,jw linking two nodes with identical labels.
Theaverages ofthe estimatedprobabilitiesarelistedinthe lastthree
columns of Table 2. The average prior means of all nodes are about
0.05, 0.15, 0.25, and 0.4, respectively for the four main groups.
Roughly speaking, it means that group 1 is in favor of a small
number, and group 4 a large number, while groups 2 and 3 in
between, of nodes labeled with +1. Furthermore, values of (t0,t1) in
subgroup b are larger than those in subgroup a, meaning that nodes
with identical labels are more likely to be next to each other apriori
in subgroup b than subgroup a, as can be seen from the last two
columns in Table 2. On the other hand, because the posteriors are
found to be insensitive to the hyperparameters (  m m,a,n,d) when n is
large, they are set to (3, 1, 10, 1) as in the previous example.
We simulate 200 data sets for each combination of the three
power settings (low, median and high) and three truly associated sets
(3, 5, and 7 nodes). For each data set, we run eight Gibbs samplers
using eight different hyperparameters described above. Each Gibbs
sampler is run with 100 restarts and each start contains 100 steps.
We compare the average AUC of 200 simulated data sets using p
value and the posterior mean and plot the results in Figure 4. In
general, the AUCof the proposed method is larger than that using p
values alone. It achieves good AUC if the prior mean is close to the
truth, especially when the power is low. For example, in the middle
column panels where there are 5 truly associated genes, prior
settings 2 and 3, favoring median number of truly associated nodes,
outperformpriorsettings1and 4.Similarly,inthe rightpanelwhere
the true model contains 7 genes, prior settings 3 and 4, which are in
favor of large models, perform better than the other prior settings.
Furthermore, priors in subgroup b are better than subgroup a in
general. It is not surprising because the priors in subgroup b
encourages nodes labeled with +1 to group together, which agrees
with the simulation setting.
To evaluate the control of the false positive rates and the false
discovery rates of the proposed methods in relatively large pathways
with only a few associated genes, we conduct a third simulation
study based on a simulated network shown in Figure 5 that contains
60 nodes. We consider three truly associated gene sets, namely (2,
11, 19), (2, 11, 19, 41), and (2, 11, 19, 20, 41), and label them as
models 1, 2 and 3 in Table 3. Similar to the previous study, we
simulate p values from z scores randomly drawn from N(1,1),
N(1:5,1) and N(2,1), corresponding to weak, median and strong
associations, respectively. Three prior settings are considered for
(h,t1,t0), namely (21.5, 0.15, 0.02), (21.50, 0.10, 0.01) and (22,
Figure 2. A simple 6-node network.
doi:10.1371/journal.pgen.1001353.g002
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mately 0.2, and average prior probabilities Pr(Si~Sj~1) for
vi,jw[ E are roughly 0.13, 0.11, and 0.08, respectively. For the
proposed method, we consider three decision rules. The first one
(PM1) uses the posterior mean with a cut-off value m 
1~0:5 as in (5),
the second one is MCP as in (4), and the third one (PM2) is the
method to control the FDR at 0.1 as in (6). Then we compare them
withthe p value method (P value) witha cut-off value setat 0.05and
the correction method (BH) of Benjamini & Hochberg (1995) [21].
For each scenario we simulate 100 data sets, and run a Gibbs
sampler with 100 restarts where each start contains 100 iterations.
Foreachsimulated data set, wecalculatetheFPR, sensitivity(Sens.),
FDR,andAUCasbefore. Table 3 liststhe averagevaluesofthe100
simulation runs. In general PM1 and MCP control the FPR below
the 0.05 level and have lower FDR than the p value while achieving
better or similar power as the p value method. In terms of
controlling FDR, PM2 controls the FDR around 0.1, and it has
smaller FPR or better power than the BH method in most cases
when it achieves similar or better FDR.
Crohn’s disease data
We use one Crohn’s disease [15] data set to further evaluate the
performance of the proposed method. Details of this data can be
found in the Materials and Methods section.
Table 1. Average FPR, sensitivities, FDR, and AUC of the 6-node network.
Prevelance Effect Size MAF=0.05 MAF=0.10 MAF=0.15
Method FPR Sens. FDR AUC FPR Sens. FDR AUC FPR Sens. FDR AUC
0.05 1.05 p value 0.05 0.06 0.42 0.50 0.05 0.07 0.39 0.52 0.04 0.08 0.35 0.54
Posterior 0.04 0.07 0.39 0.55 0.04 0.08 0.35 0.56 0.04 0.08 0.33 0.59
1.10 p value 0.05 0.08 0.38 0.55 0.05 0.12 0.25 0.60 0.05 0.13 0.26 0.60
Posterior 0.05 0.08 0.38 0.60 0.04 0.13 0.22 0.65 0.04 0.16 0.21 0.67
1.15 p value 0.05 0.13 0.25 0.60 0.04 0.20 0.18 0.67 0.06 0.28 0.17 0.72
Posterior 0.04 0.15 0.21 0.67 0.04 0.23 0.16 0.74 0.05 0.33 0.13 0.80
1.20 p value 0.05 0.18 0.19 0.64 0.04 0.32 0.10 0.76 0.05 0.40 0.11 0.81
Posterior 0.05 0.20 0.17 0.71 0.04 0.38 0.09 0.84 0.05 0.49 0.09 0.88
1.25 p value 0.05 0.25 0.16 0.70 0.06 0.41 0.12 0.80 0.05 0.56 0.07 0.88
Posterior 0.05 0.29 0.14 0.77 0.06 0.51 0.10 0.87 0.06 0.68 0.06 0.93
1.30 p value 0.05 0.34 0.11 0.76 0.05 0.57 0.07 0.88 0.05 0.72 0.05 0.92
Posterior 0.05 0.41 0.10 0.83 0.06 0.68 0.06 0.93 0.05 0.83 0.05 0.96
0.1 1.05 p value 0.05 0.06 0.43 0.54 0.05 0.08 0.39 0.52 0.05 0.07 0.41 0.53
Posterior 0.05 0.07 0.42 0.58 0.05 0.08 0.39 0.58 0.05 0.07 0.38 0.59
1.10 p value 0.05 0.09 0.34 0.57 0.04 0.13 0.24 0.60 0.05 0.16 0.25 0.62
Posterior 0.04 0.09 0.31 0.62 0.04 0.15 0.20 0.66 0.05 0.18 0.21 0.70
1.15 p value 0.04 0.14 0.22 0.62 0.05 0.21 0.18 0.67 0.05 0.27 0.14 0.72
Posterior 0.04 0.15 0.20 0.69 0.05 0.24 0.16 0.73 0.05 0.33 0.11 0.80
1.20 p value 0.04 0.21 0.16 0.68 0.05 0.33 0.12 0.77 0.05 0.45 0.09 0.82
Posterior 0.04 0.24 0.14 0.76 0.06 0.40 0.11 0.84 0.06 0.54 0.08 0.89
1.25 p value 0.05 0.27 0.13 0.73 0.05 0.48 0.08 0.84 0.04 0.62 0.05 0.91
Posterior 0.04 0.33 0.11 0.80 0.05 0.57 0.06 0.90 0.05 0.73 0.05 0.95
1.30 p value 0.05 0.37 0.12 0.79 0.05 0.61 0.05 0.90 0.05 0.78 0.04 0.94
Posterior 0.05 0.46 0.09 0.87 0.05 0.73 0.05 0.94 0.05 0.87 0.04 0.97
0.2 1.05 p value 0.06 0.06 0.50 0.52 0.05 0.08 0.39 0.54 0.06 0.09 0.39 0.55
Posterior 0.05 0.06 0.49 0.55 0.04 0.08 0.33 0.59 0.05 0.09 0.36 0.59
1.10 p value 0.06 0.09 0.39 0.53 0.05 0.13 0.26 0.60 0.06 0.17 0.24 0.64
Posterior 0.05 0.09 0.36 0.58 0.04 0.15 0.22 0.66 0.04 0.20 0.18 0.71
1.15 p value 0.05 0.15 0.24 0.63 0.04 0.24 0.14 0.71 0.04 0.37 0.10 0.78
Posterior 0.05 0.18 0.20 0.69 0.05 0.28 0.13 0.79 0.05 0.44 0.10 0.85
1.20 p value 0.05 0.24 0.18 0.70 0.05 0.43 0.10 0.81 0.04 0.55 0.06 0.89
Posterior 0.05 0.28 0.15 0.78 0.05 0.52 0.08 0.88 0.05 0.67 0.06 0.93
1.25 p value 0.05 0.35 0.12 0.78 0.05 0.57 0.06 0.88 0.04 0.73 0.04 0.94
Posterior 0.05 0.43 0.09 0.84 0.05 0.68 0.05 0.94 0.05 0.82 0.04 0.97
1.30 p value 0.05 0.46 0.08 0.83 0.05 0.73 0.05 0.93 0.05 0.86 0.04 0.97
Posterior 0.06 0.57 0.08 0.90 0.06 0.84 0.05 0.97 0.05 0.93 0.04 0.99
doi:10.1371/journal.pgen.1001353.t001
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genes with non-missing p values. The hyperparameters (h,t1,t0)
are chosen such that the average prior mean is roughly between
0.2 and 0.4 based on the simulation findings. To evaluate the
performance, we consider 32 target genes that are confirmed to
be related to the Crohn’s disease [22]. Among these genes, 10
genes can be mapped to 66 pathways. In Figure 6 we plot the
AUC values of the rankings by p values on the y axis and
posterior means on the x axis for pathways containing three or
more target genes. A majority of AUC values are improved if
genes are rank ordered by the posterior mean. The average AUC
based on p values is 0.568 while on posterior means is 0.613. To
see what causes the rank changes of genes in the posterior
probability, in Figure 7 we show the Human IL-2 Receptor Beta
Chain in T cell Activation pathway from BioCarta. Genes in this
pathway are densely connected. To aid visualization, we
randomly remove some edges. Significant genes whose p values
are below 0.05 are colored in cyan, genes with improved ranks
are colored in light blue and others are colored in pink. It can be
clearly seen that genes colored in light blue have more
connections with the significant genes, and are more heavily
linked among themselves, compared to other genes in the
pathway. Genes that have many interactions with each other
may play important roles in the biological processes in the
pathway. When they are connected to many significant genes, it
might be reasonable that they are more likely to associate with
the disease than other genes.
Discussion
In this article we introduced a Bayesian method to incorporate
prior knowledge of biological pathways into GWAS. This
approach uses a MRF as a prior distribution to model the
interactions among genes that participate in the same pathway.
We showed that the posterior distribution is also a MRF and can
be sampled via a Gibbs sampler. Inferences based on the
posterior distribution allow us to combine data from the
association study with prior information of biological pathways.
In particular, this framework considers the topology of all genes
in a pathway, which has not been fully utilized in many of the
existing methods. The simulation studies and real data example
suggest that the proposed method has higher power to identify
genes associated with disease.
One limitation of the MRF model is that the Gibbs sampler tends
to move around local maxima for a long time and thus can be slow
in convergence to the posterior distribution. We recommend to run
the Markov chain Monte Carlo with multiple random restarts, and
examine the sampling distribution of network statistics, like the
numberofgenes labeled with +1 and the proportion ofedges linking
genes with identical labels. In our studies, we found that a Markov
chain initially moves very rapidly from its starting state, usually
within the first 10 to 20 steps, before it reaches some steady states
and stabilizes for a long period thereafter. We suggest running 100
Gibbs steps for each random starting state, and conducting the
simulation with 100 restarts. The computing time of this scheme
typically takes a few minutes on a PC for a pathway of about 30
genes. We should also mention that the characteristics of the MRF
defined in (1) depend on both the hyperparameters and the
structure of the network under consideration. Consequently there
does not exist a set of hyperparameters that can be suitable for all
pathways. To assist the specification of hyperparameters, we
provide an algorithm of estimating hyperparameters based on a
Figure 3. A 31-node network adapted from BioCarta ‘‘Human
Rho cell motility signaling pathway.’’ Triangles, rectangles and
pentagons denote three different sets of truly associated genes, each of
which contains three, five, and seven nodes, respectively.
doi:10.1371/journal.pgen.1001353.g003
Table 2. Eight priors.
Hyperparameters Estimates
Group Subgroup h t1 t0 E½Pr(Si~1)  E½Pr(Si~Sj~1)  E½Pr(Si~Sj~{1) 
1 a 23.00 0.10 0.01 0.044 0.003 0.917
b 23.00 0.25 0.10 0.049 0.043 0.923
2 a 22.00 0.10 0.01 0.156 0.047 0.710
b 22.50 0.20 0.05 0.141 0.119 0.776
3 a 21.25 0.05 0.01 0.250 0.081 0.563
b 23.00 0.25 0.05 0.254 0.264 0.602
4 a 21.50 0.10 0.01 0.355 0.227 0.402
b 22.00 0.25 0.10 0.405 0.412 0.466
doi:10.1371/journal.pgen.1001353.t002
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mended that these values would be used in initial attempts and it
would be better to test several other variants of hyperparameters,
possibly through fine-tuning the initial values. It is helpful to draw
samples from the prior distribution to assess the effects o f different
prior settings. One limitation of pathway-based analysis is that not
all the genes can be associated with pathways. It is likely with
knowledge accumulation, more genes will be mapped to pathways.
An R package is under construction and will be made publically
available soon.
Materials and Methods
The MRF property of the prior distribution on pathways
The nearest neighbor Gibbs measure on gene pathways in
formula (1) defines a MRF and its conditional distribution has a
logistic regression form as shown below.
Proposition 1. The Gibbs measure in (1) is Markovian and
thus defines a MRF
Pr(SiDSV{i,h0)~Pr(SiDSNi,h0):
Moreover, the conditional distribution has a logistic form:
logitPr(SijSNi,h0)~hzt1 wiJ
(1)
i z
X
k [ Ni
wkI1(Sk)
0
@
1
A{
t0 wiJ
({1)
i z
X
k [ Ni
wkI{1(Sk)
0
@
1
A, i~1,   ,n,
ð7Þ
where J
(l)
i ~
X
k [ Ni Il(Sk), l~+1. Equivalently, (7) can be
rewritten as a system of linear equations:
logitPr(SiDSNi,h0)~bi0zbi1S1z   zbinSn, i~1,   ,n, ð8Þ
Figure 4. Comparison under different priors. The three rows of panels are for weak (top panel), median (middle panel), and strong (bottom
panel) association signals. The three columns of panels are for three sets of truly associated genes corresponding to three (left), five (middle), and
seven (right) nodes, respectively. The dotted lines link AUC of the proposed method and the solid lines connect AUC using p values. Circles, triangles,
plus signs and crosses denote prior parameter groups 1, 2, 3, and 4, respectively.
doi:10.1371/journal.pgen.1001353.g004
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bi0~h,
bij~
0 if i~jo rvi,jw 6[ E
(wizwj)ft1I1(Sj){t0I{1(Sj)g if vi,jw[ E:
 
Proof. See Text S1.
This result shows the Markov property that the conditional
distribution of Si, given all other node labels in the network, is
equal to the conditional distribution of Si given all its neighbors. It
follows immediately from (8) that if Si and Sj are not neighbors,
then they are conditionally independent.
Now we give an interpretation of wi. From (8), it is clear that the
conditional distribution of Si depends on the weighted sum of
labels of its neighbors, with weight (wizwj)t1 if Sj~1 and
{(wizwj)t0 if Sj~{1. Here (wizwj) is the sum of weights on
both ends of a linking edge. We set wi to be the square root of of
di, which is the degree of gene i. As a result, a gene that interacts
with many other genes in the pathway has a large weight because
it may play a central role in a biological process and thus it is likely
to have a large influence.
The Markovian property of (1) can be derived directly from a
more general result [18], which states that a nearest neighbor
Gibbs measure is equivalent to a MRF. Our proof that is
specific to (1) and is needed to derive the logistic model in (7).
We note that under the setting of rectangular lattice systems,
Besag [23,24] presented a general logistic model called the auto-
logistic model.
Figure 5. A simulated 60-node network.
doi:10.1371/journal.pgen.1001353.g005
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To see that the posterior distribution is also a MRF, note that
for node i,
Pr(Si~z1Dy,SV{i,h0,h1) ! f1(yiDh1)Pr(Si~z1DSV{i,h0)
~f1(yiDh1)Pr(Si~z1DSNi,h0):
Thus, the conditional posterior distribution of Si given all other
nodes only depends on its neighbors, which means the posterior
distribution is also a MRF. The conditional posterior log odds of
Si is
hzlogLR(yi;h1)zt1 wiJ
(1)
i z
X
k [ Ni
wkI1(Sk)
0
@
1
A{
t0 wiJ
({1)
i z
X
k [ Ni
wkI{1(Sk)
0
@
1
A,
ð9Þ
where
LR(yi;h1)~
f1(yiDh1)
f0(yi)
Table 3. Average FPR, sensitivities, FDR, and AUC of the 60-node simulated network.
Weak Association Median Association Strong Association
Model Method FPR Sens. FDR AUC FPR Sens. FDR AUC FPR Sens. FDR AUC
1 P Value 0.0470 0.157 0.817 0.629 0.0516 0.297 0.745 0.739 0.0523 0.533 0.621 0.863
BH 0.0021 0.037 0.085 0.0014 0.043 0.070 0.0032 0.187 0.098
Prior 1 PM1 0.0412 0.167 0.790 0.657 0.0468 0.297 0.695 0.776 0.0496 0.567 0.591 0.899
MCP 0.0370 0.150 0.768 0.0418 0.253 0.696 0.0454 0.523 0.593
PM2 0.0018 0.030 0.087 0.0014 0.050 0.075 0.0026 0.187 0.120
Prior 2 PM1 0.0404 0.163 0.792 0.653 0.0437 0.290 0.689 0.768 0.0472 0.543 0.585 0.890
MCP 0.0375 0.150 0.779 0.0416 0.277 0.689 0.0449 0.523 0.583
PM2 0.0016 0.030 0.085 0.0021 0.090 0.110 0.0025 0.177 0.115
Prior 3 PM1 0.0300 0.143 0.688 0.690 0.0326 0.293 0.592 0.795 0.0377 0.577 0.483 0.907
MCP 0.0253 0.140 0.648 0.0270 0.247 0.594 0.0337 0.500 0.480
PM2 0.0023 0.040 0.107 0.0012 0.053 0.065 0.0019 0.187 0.100
2 P Value 0.0457 0.173 0.730 0.629 0.0514 0.330 0.668 0.738 0.0505 0.465 0.565 0.840
BH 0.0018 0.018 0.090 0.0027 0.035 0.100 0.0038 0.178 0.094
Prior 1 PM1 0.0389 0.168 0.694 0.659 0.0450 0.340 0.621 0.788 0.0446 0.508 0.523 0.879
MCP 0.0370 0.145 0.701 0.0416 0.318 0.618 0.0411 0.490 0.515
PM2 0.0020 0.018 0.110 0.0016 0.050 0.085 0.0016 0.178 0.075
Prior 2 PM1 0.0379 0.170 0.692 0.653 0.0439 0.323 0.624 0.775 0.0430 0.490 0.522 0.869
MCP 0.0370 0.153 0.694 0.0413 0.305 0.626 0.0413 0.468 0.530
PM2 0.0020 0.018 0.110 0.0016 0.048 0.085 0.0020 0.158 0.095
Prior 3 PM1 0.0289 0.143 0.639 0.683 0.0364 0.320 0.583 0.803 0.0352 0.485 0.469 0.888
MCP 0.0252 0.125 0.610 0.0321 0.288 0.577 0.0293 0.455 0.454
PM2 0.0014 0.018 0.080 0.0013 0.048 0.065 0.0027 0.205 0.108
3 P Value 0.0478 0.148 0.756 0.648 0.0476 0.326 0.591 0.744 0.0458 0.524 0.468 0.856
BH 0.0038 0.028 0.129 0.0015 0.050 0.051 0.0029 0.166 0.052
Prior 1 PM1 0.0402 0.136 0.744 0.675 0.0425 0.336 0.544 0.794 0.0409 0.584 0.422 0.897
MCP 0.0364 0.124 0.737 0.0387 0.320 0.545 0.0373 0.568 0.403
PM2 0.0027 0.022 0.150 0.0011 0.056 0.053 0.0020 0.230 0.060
Prior 2 PM1 0.0404 0.134 0.738 0.669 0.0411 0.318 0.559 0.779 0.0398 0.556 0.427 0.886
MCP 0.0380 0.124 0.749 0.0393 0.302 0.559 0.0375 0.546 0.414
PM2 0.0025 0.026 0.140 0.0009 0.052 0.045 0.0018 0.206 0.062
Prior 3 PM1 0.0282 0.120 0.654 0.700 0.0333 0.310 0.486 0.806 0.0315 0.556 0.381 0.904
MCP 0.0247 0.100 0.620 0.0280 0.270 0.479 0.0276 0.540 0.358
PM2 0.0020 0.014 0.110 0.0011 0.046 0.055 0.0015 0.216 0.052
doi:10.1371/journal.pgen.1001353.t003
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marginal likelihood ratio, reflecting the evidence from the data for
association with the disease, and the conditional prior odds,
reflecting the effect from interactions among neighboring genes
from the biological pathway.
To make it clear, we can rewrite (9) in the form of a system of
auto-logistic regression equations:
logitPr(SiDy,SV{i,h0,h1)~b
0
i0zbi1S1z   zbinSn,i~1,   ,n, ð10Þ
Figure 6. AUC comparison of rankings by p values and posterior means for Crohn’s disease data. AUC values of the rankings by p values
are on the y axis and that of the posterior means are on the x axis for pathways containing three or more target genes.
doi:10.1371/journal.pgen.1001353.g006
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Figure 7. IL-2 receptor Beta chain in T cell activation pathway. Significant genes whose p values are below 0.05 are colored in cyan, genes
with improved ranks are colored in light blue and others are colored in pink.
doi:10.1371/journal.pgen.1001353.g007
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b
0
i0~hzlogLR(yi;h1),
bij~
0i f i~j or vi,jw 6[ E
(wizwj)ft1I1(Sj){t0I{1(Sj)g if vi,jw[ E
 
There are a few observations. First, it is easy to see that the
posterior conditional logit form in (9) is the same as the prior
conditional logit in (8) except its intercept is hzlogLR(yi;h1).
Thus, the observed log likelihood ratio provides a fixed additive
effect to the prior logit. Second, the coefficient matrix is
symmetric, i.e., bij~bji. If gene i and j are not neighbors, then
bij~bji~0 and they are conditionally independent. On the other
hand, if they are neighbors, then the impact between each other is
equal. Third, genes i and j are in general correlated in their joint
posterior distribution, even if they are not neighbors and are
conditionally independent. Moreover, the more common neigh-
bors they share with each other, the stronger the correlation
between the two.
The MCMC algorithm
To sample from the posterior distribution, here we implement a
Gibbs sampler that is well suited for a MRF. The algorithm is
described as follows. First we set an initial value for S, say s(0).
Then in step k, we update the labels sequentially for i~1,   ,n
according to (10):
logitPr(s
(k)
i Dy,s
(k)
1 ,   ,s
(k)
i{1,s
(k{1)
iz1 ,   ,s(k{1)
n ,h0,h1)
~b
0
i0zbi1s
(k)
1 z   zbi,i{1s
(k)
i{1zbi,iz1s
(k{1)
iz1 z   zbins(k{1)
n ,
to obtain s(k) from s(k{1). In each cycle we may want to randomize
the order in which the nodes are updated.
Crohn’s disease data
The Crohn’s disease [15] data set is used to evaluate the
performance of the proposed method in the Results section.
Crohn’s disease is a type of inflammatory bowel disease
characterized by chronic inflammation of discontinuous segments
of the intestine. The disease is found to be related to the
interaction of several factors including genetic susceptibility, the
intestinal microbial flora of the patient, the patient’s immune
response to these microbiota, and environmental triggers [25]. It
has been well established that Crohn’s disease has a strong genetic
component [26].
The cohort used in the analysis includes 401 cases and 433
controls. SNPs with a call rate greater than 0.9, minor allele
frequency greater than 0.01, and HWE p value greater than 0.001
are kept, while subjects with a call rate less than 0.95 are removed
from the analysis. Finally 397 cases and 431 controls remain in the
analysis. SNPs are considered being mapped to a gene if their
physical locations are within +10 kb from the start or end point of
the gene as given by Refseq annotation at the NCBI website. Gene
level p values are obtained by regressing disease status on PCA
components that account for at least 85% of the variation [27–29].
The pathways and genes in each pathway as well as the gene-level
p values can be found at http://bioinformatics.med.yale.edu/
group/software.html.
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